Skip to main content

Table 1 Baseline characteristics, preoperative clinical and laboratory data and histopathological characteristics of patients with pancreatic ductal adenocarcinoma (PDAC) (n = 236)

From: Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma

  n = 236
Age at the time of surgery (in years) 67.5 (39.2–85.9)
Sex, male / female 123 (52.1%) / 113 (47.9%)
ASA class
  I–II 110 (46.6%)
  III–IV 126 (53.4%)
BMI (kg/m2) (n = 210) 25.3 (15.8–40.1)
Tobacco smoking (n = 227)
  Never smoker 115 (48.7%)
  Current smoker 46 (19.5%)
  Former smoker 58 (24.6%)
Alcohol consumption (n = 231)
 Ongoing alcohol misuse 20 (8.5%)
 Heavy alcohol intake (ever) 28 (11.9%)
History of diabetes mellitus
  No 174 (73.7%)
  Yes 62 (26.3%)
  Duration of diabetes, in months (n = 34) 12.0 (1.0–336.0)
Blood type
  A 117 (49.6%)
  B 40 (16.9%)
  AB 27 (11.4%)
  O 52 (22.0%)
Symptoms
  Jaundice (n = 235) 184 (78.0%)
  Abdominal or back pain (n = 235) 105 (44.5%)
  Weight loss (n = 234) 96 (40.7%)
  Steatorrhea (n = 234) 26 (11.0%)
Preoperative imaging
  CT 232 (98.3%)
  MRCP 67 (28.4%)
  Upper abdominal MRI 61 (25.8%)
  US 199 (84.3%)
  EUS 29 (12.3%)
  EUS-FNA 18 (7.6%)
  FDG-PET-CT 5 (2.1)
Preoperative blood test
  CRP (mg/l) (n = 149) 5.0 (1.0–124.0)
  High-sensitivity CRP (mg/l) (n = 186) 3.4 (0.06–135.5)
  Total bilirubin (μmol/l) 17.0 (4.0–511.0)
  Ca 19–9 (kU/l) (n = 231) 139.0 (1.0–35,770.0)
  CEA (μg/l) (n = 229) 2.7 (1.0–68.9)
  Albumin (g/l) (n = 234) 36.5 (22.6–46.5)
Location of pancreatic cancer
  Head of the pancreas 232 (99.2%)
  Body of the pancreas 2 (0.8%)
T status (n = 235)
  T1 25 (10.6%)
  T2 164 (69.5%)
  T3 37 (15.7%)
  T4 9 (3.8%)
LN metastasis (n = 234)
  N0 62 (26.3%)
  N1 171 (72.5%)
  N2 1 (0.4%)
Tumor size (mm) (n = 232)
  ≤30 mm 123 (52.1%)
  > 30 mm 109 (46.2%)
Perivascular invasion (n = 201) 77 (32.6%)
Perineural invasion (n = 216) 174 (73.7%)
R status (n = 231)
  R0 178 (75.4%)
  R1 55 (22.5%)
Adjuvant chemotherapy 147 (62.3%)
  1. Figures consist of the number of patients (%) or median (range)
  2. Abbreviations: ASA American Society of Anesthesiologists; BMI body mass index; CT computed tomography; DM diabetes mellitus; EUS endoscopic ultrasound; EUS-FNA endoscopic ultrasound-guided fine needle aspiration biopsy; FDG-PET-CT fluorodeoxyglucose (FDG) positron emission tomography (PET); MRCP magnetic resonance cholangiopancreatography; MRI magnetic resonance imaging; US ultrasound